Conduit Pharmaceuticals (Conduit Pharmaceuticals) Quality Rank

View and export this data going back to 2023. Start your Free Trial

What is Conduit Pharmaceuticals Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Conduit Pharmaceuticals Quality Rank Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Conduit Pharmaceuticals (Conduit Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (NAS:CDT) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

4995 Murphy Canyon Road, Suite 300, San Diega, CA, USA, 92123

Website

https://www.conduitpharma.com

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Executives

Intelmed Llc	other: See Responses	11421 GOLDEN EAGLE COURT, NAPLES FL 34120
Jennifer Isacoff Mcnealey	director	C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121
David Tapolczay	director, officer: Chief Executive Officer	32 CROUCH HALL LANE, ST. ALBANS X0 AL3 7EU
Andrew Regan	director, 10 percent owner	LE MANOIR DE LURIN, SAINT BARTHELEMY Z0 97133
Faith L. Charles	director	ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS - FLOOR 33, NEW YORK NY 10019
Algo Holdings, Inc.	10 percent owner, other: See Responses	100 W. CYPRESS CREEK ROAD, STE. 640, FORT LAUDERDALE NY 33309
Corvus Capital Ltd.	10 percent owner, other: See Responses	WILLOW HOUSE, CRICKET SQUARE PO BOX 709, GRAND CAYMAN E9 KY1 - 1107
Freda C Lewis-hall	director	C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
James Bligh	director	38 OXBERRY AVENUE, LONDON X0 SW6 5SS
Shaolin Capital Management Llc	10 percent owner	230 NW 24TH STREET, SUITE 603, MIAMI FL 33127
Richard Edward Feinberg	director	2855 FIFTH AVENUE, UNIT 405, SAN DIEGO CA 92103
Murphy Canyon Acquisition Sponsor, Llc	10 percent owner	4995 MURPHY CANYON ROAD, SUITE 300, SAN DIEGO CA 92123
Chele Chiavacci Farley	director	4 RIDGE ROAD, TUXEDO PARK NY 10987
Bentzen Edwin H Iv	officer: Chief Accounting Officer	2513 BIRCH HOLLOW ST, HENDERSON NV 89044
Jack Kendrick Heilbron	director, officer: CEO, President, and Chairman	16433 BRONCO LANE, POWAY CA 92064